MedPath

Doxycycline

Generic Name
Doxycycline
Brand Names
Acticlate, Adoxa, Apprilon, Atridox, Doryx, Doxy, Doxycin, Lymepak, Mondoxyne, Monodox, Morgidox, Okebo, Oracea, Periostat, Targadox, Vibramycin
Drug Type
Small Molecule
Chemical Formula
C22H24N2O8
CAS Number
564-25-0
Unique Ingredient Identifier
334895S862

Overview

Doxycycline is a broad-spectrum antibiotic synthetically derived from oxytetracycline. It is a second-generation tetracycline that was first discovered in 1967. Second-generation tetracyclines exhibit lesser toxicity than first-generation tetracyclines. Doxycycline is used to treat a wide variety of gram-positive and gram-negative bacterial infections. It is also used to treat acne and malaria.

Indication

Doxycycline is indicated for the treatment of various infections by gram-positive and gram-negative bacteria, aerobes and anaerobes, as well other types of bacteria, including: It is also used to treat infections caused by the following gram-negative microorganisms:

Associated Conditions

  • Acinetobacter Infections
  • Anthrax
  • Bacterial Infection caused by Enterobacter aerogenes
  • Bartonellosis
  • Brucellosis
  • Campylobacter Infection
  • Chancroid
  • Chlamydia Trachomatis Infection
  • Early Lyme Disease
  • Granuloma Inguinale
  • Infection Due to Escherichia Coli
  • Inhalational Anthrax
  • Klebsiella Infections
  • Lymphogranuloma Venereum
  • Malaria caused by Plasmodium falciparum
  • Nongonococcal urethritis
  • Plague caused by Yersinia pestis
  • Psittacosis
  • Rectal infection caused by Chlamydia Trachomatis
  • Relapsing fever caused by Borrelia recurrentis
  • Respiratory Tract Infection Bacterial
  • Rickettsial infectious disorders
  • Severe Acne
  • Sexually Transmitted Infections (STIs)
  • Shigella Infection
  • Trachoma inclusion conjunctivitis
  • Tularemia
  • Vibrio Cholerae Infection
  • Acute Intestinal amebiasis
  • Susceptible Bacterial Infections
  • Uncomplicated endocervical infection
  • Uncomplicated urethral infection

Research Report

Published: Jul 18, 2025

A Comprehensive Monograph on Doxycycline (DB00254): Pharmacological Profile, Clinical Applications, and Safety Considerations

Introduction and Drug Identification

Overview and Classification

Doxycycline is a potent, broad-spectrum antibiotic belonging to the tetracycline class of antimicrobial agents.[1] Classified as a small molecule, it represents a significant advancement as a second-generation tetracycline, synthetically derived from its predecessor, oxytetracycline.[1] This specific chemical heritage confers a more favorable toxicity profile compared to first-generation tetracyclines, a factor that has contributed substantially to its widespread and enduring clinical use.[1]

The drug is approved for both human and veterinary applications and is also categorized as an investigational agent, reflecting a robust and ongoing pipeline of research into novel therapeutic uses.[1] Its clinical utility is notably multifaceted, extending well beyond its primary function as a bacteriostatic agent. Doxycycline possesses well-documented antiparasitic and anti-inflammatory properties, making it a versatile therapeutic tool capable of addressing a diverse range of pathological processes, from infectious diseases to chronic inflammatory conditions.[1]

Chemical and Physical Properties

The definitive identification of doxycycline is established through several key chemical and physical descriptors. It is uniquely identified by the Chemical Abstracts Service (CAS) Number 564-25-0 and the DrugBank Accession Number DB00254.[1]

Continue reading the full research report

FDA Drug Approvals

Approved Product
Manufacturer
NDC Code
Route
Strength
Effective Date
Aphena Pharma Solutions - Tennessee, LLC
71610-117
ORAL
100 mg in 1 1
10/31/2018
H.J. Harkins Co., Inc.
76519-1134
ORAL
100 mg in 1 1
3/11/2018
A-S Medication Solutions
50090-1462
ORAL
100 mg in 1 1
5/28/2025
Tris Pharma Inc
27808-234
ORAL
100 mg in 1 1
2/11/2022
Denton Pharma, Inc. DBA Northwind Pharmaceuticals
70934-996
ORAL
100 mg in 1 1
1/1/2023
JG Pharma Inc.
72143-211
ORAL
50 mg in 1 1
3/20/2019
Bryant Ranch Prepack
72162-2256
ORAL
20 mg in 1 1
12/27/2023
RedPharm Drug, Inc.
67296-0329
ORAL
100 mg in 1 1
3/1/2021
Amneal Pharmaceuticals NY LLC
69238-1100
ORAL
100 mg in 1 1
12/29/2023
American Health Packaging
62584-693
ORAL
100 mg in 1 1
9/26/2023

EMA Drug Approvals

Approved Product
Authorization Holder
Status
Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product
Manufacturer
Approval Number
Dosage Form
Strength
Approval Date
APO-DOXY-TABS 100 mg
SIN08445P
TABLET, FILM COATED
100 mg
11/24/1995
DOXYLINE CAPSULE 100 mg
SIN10340P
CAPSULE
100 mg
11/4/1998
MICRODOX CAPSULE 100 mg
SIN08536P
CAPSULE
100 mg
2/5/1996
DOXYLINE ENTERIC COATED CAPSULE 100 mg
SIN08388P
CAPSULE
100 mg
10/16/1995
TETRADOX CAPSULE 100 mg
SIN06906P
CAPSULE
100 mg
3/20/1992
DOXYCAP CAPSULE U.S.P. 100 mg
SIN08101P
CAPSULE
100 mg
4/5/1995
DOXYMYCIN-100 CAPSULES 100 mg
SIN02205P
CAPSULE
100mg
6/29/1988
MEDOMYCIN CAPSULE 100 mg
SIN00968P
CAPSULE
100 mg
5/10/1988

NMPA Drug Approvals

Approved Product
Company
Approval Number
Drug Type
Dosage Form
Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product
Registration No.
Company
Licence No.
Strength
Registration Date
No PPB approvals found for this drug.

Health Canada Drug Approvals

Approved Product
Company
DIN
Dosage Form
Strength
Market Date
RHO-DOXYCIN - CAP 100MG
rhodiapharm inc
02144190
Capsule - Oral
100 MG / CAP
12/31/1995
RHO-DOXYCIN TABS - 100MG
rhodiapharm inc
02144204
Tablet - Oral
100 MG / TAB
12/31/1995

CIMA AEMPS Drug Approvals

Approved Product
Company
Registration Number
Pharmaceutical Form
Prescription Type
Status
DOXICLAT 100 mg COMPRIMIDOS RECUBIERTOS CON PELICULA
Pierre Fabre Iberica S.A.
50404
COMPRIMIDO RECUBIERTO
Medicamento Sujeto A Prescripción Médica
Commercialized
DOXIPIL 100 mg CAPSULAS DURAS
Laboratorio Reig Jofre, S.A.
59345
CÁPSULA DURA
Medicamento Sujeto A Prescripción Médica
Not Commercialized
ORACEA 40 mg CAPSULAS DURAS DE LIBERACION MODIFICADA
Laboratorios Galderma S.A.
73622
CÁPSULA DURA DE LIBERACIÓN MODIFICADA
Medicamento Sujeto A Prescripción Médica
Commercialized

Philippines FDA Drug Approvals

Approved Product
Company
License Number
Dosage Form
Strength
Approval Date
No Philippines FDA approvals found for this drug.

Saudi SFDA Drug Approvals

Approved Product
Company
License Number
Dosage Form
Strength
Approval Date
No Saudi SFDA approvals found for this drug.

Malaysia NPRA Drug Approvals

Approved Product
Company
Registration Number
Dosage Form
Strength
Approval Date
No Malaysia NPRA approvals found for this drug.

UK EMC Drug Information

Medicine Name
MA Holder
MA Number
Pharmaceutical Form
Active Ingredient
Authorization Date
No UK EMC drug information found for this drug.

Help Us Improve

Your feedback helps us provide better drug information and insights.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.